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Available online 4 December 2011Human African trypanosomiasis (HAT) is a parasitic disease affecting sub-Saharan Africa.
The parasites are able to traverse the blood–brain barrier (BBB), which marks stage 2 (S2)
of the disease. Delivery of anti-parasitic drugs across the BBB is key to treating S2 effectively
and the difficulty in achieving this goal is likely to be a reason why some drugs require high-
ly intensive treatment regimes to be effective. This study aimed to investigate not only the
drug transport mechanisms utilised by nifurtimox at the BBB, but also the impact of nifur-
timox–eflornithine combination therapy (NECT) and other anti-HAT drug combination
therapies (CTs) on radiolabelled-nifurtimox delivery in an in vitro model of drug accumula-
tion and the human BBB, the hCMEC/D3 cell line. We found that nifurtimox appeared to use
several membrane transporters, in particular breast-cancer resistance protein (BCRP), to
exit the BBB cells. The addition of eflornithine caused no change in the accumulation of
nifurtimox, nor did the addition of clinically relevant doses of the other anti-HAT drugs sur-
amin, nifurtimox or melarsoprol, but a significant increase was observed with the addition
of pentamidine. The results provide evidence that anti-HAT drugs are interacting with
membrane transporters at the human BBB and suggest that combination with known trans-
port inhibitors could potentially improve their efficacy.
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112 B R A I N R E S E A R C H 1 4 3 6 ( 2 0 1 2 ) 1 1 1 – 1 2 11. IntroductionHuman African Trypanosomiasis (HAT) is caused by Trypano-
soma brucei gambiense (T. b. gambiense) and Trypanosoma brucei
rhodesiense (T. b. rhodesiense), two species of parasitic protozoans
belonging to the genus Trypanosoma. The trypanosomes are
spread by the biting Tsetse fly which acts as an intermediate
host. The disease, if left untreated, then manifests as two dis-
tinct stages. The first stage (S1) is generally asymptomatic and
characterized by presence of the parasites in the blood and lym-
phatic systems of the human host. The second stage (S2) is
characterized by parasites in the brain and cerebrospinal fluid
(CSF) and can occurmonths (T. b. rhodesiense) or years (T. b. gam-
biense) after the initial infection. In S2, a variety of central ner-
vous system (CNS) disorders become apparent including
insomnia and changes in sleeping cycle which give the disease
the name ‘sleeping sickness’ (for a recent review of HAT's ef-
fects on the CNS see Kristensson et al., 2010). If HAT remains
untreated it is fatal, thus anti-parasitic chemotherapy is crucial.
Fortunately, several drugs are available to treat the disease but
have different efficacies depending on the disease stage and
pathogen being targeted. The drugs also pose several other
problems; they can be expensive, require intensive administra-
tion programmes which are unrealistic in a resource poor set-
ting and some are toxic to patients. Treatment of S2 requires
that the drug crosses the blood–brain barrier (BBB); the highly
specialised microvasculature that separates the cerebral tissue
from the blood circulation (Abbott et al., 2006). S1 acting drugs
are pentamidine and suramin which are effective against T. b.
gambiense and T. b. rhodesiense, respectively (Brun et al., 2010;
Sanderson et al., 2007; Sands et al., 1985). S2 drugs are melarso-
prol, eflornithine and nifurtimox. Several recent reviews dis-
cuss the S2 acting drugs in further detail (Brun et al., 2010;
Lutje et al., 2010).
Our research group has investigated the ability of suramin,
pentamidine, eflornithine and nifurtimox to cross the BBB
using an in situ brain/choroid plexus perfusion technique in
anaesthetised mice (Jeganathan et al., 2011; Sanderson et al.,
2007, 2008, 2009). Our latest study focused on nifurtimox, an
anti-parasitic nitrofuran that was originally used to treat Cha-
gas disease; a closely related condition to HAT caused by Try-
panosoma cruzi (Gonnert and Bock, 1972; Haberkorn and
Gonnert, 1972), but has since been used in compassionate
treatment for HAT when other methods have failed (Moens
et al., 1984; Van Nieuwenhove, 1992). Nifurtimox is now used
against S2 in combination with eflornithine (Checchi et al.,
2007). Nifurtimox is cheap, orally active and effective against
T. b. gambiense and, to a lesser extent, T. b. rhodesiense
(Bouteille et al., 2003; Haberkorn, 1979; Lutje et al., 2010). Im-
portantly, our group have shown that nifurtimox is able to
cross the murine BBB in situ, but undergoes an efflux removal
process from the brain via an unidentified process, in which
the adenosine triphosphate (ATP) binding cassette (ABC)
transporter P-glycoprotein, (P-gp) is not involved (Jeganathan
et al., 2011). The identify of this efflux mechanism is of special
interest with the fact that nifurtimox–eflornithine combina-
tion therapy (NECT) is now becoming the first course of treat-
ment against S2 HAT (Yun et al., 2010), having been shown to
both improve efficacy and reduce harmful side effects (Priottoet al., 2007, 2009). The precisemechanisms behind the success
of this particular combination therapy (CT) have yet to be fully
revealed, however, it is possible CT could improve delivery to
the brain. Our group have shown that nifurtimox delivery to
themouse brain is improved with the addition of the S1 acting
drug pentamidine (Jeganathan et al., 2011), which we have
previously identified as being a substrate for cellular transport
mechanisms at the BBB, including P-gp (Sanderson et al.,
2009). These findings highlight not only the need to elucidate
the transport mechanisms utilized by nifurtimox at the BBB,
but also the effect of CT on its delivery.
Our earlier work has focused on in vivomurinemodels of the
BBB, however, in order to translate the research to the human
situation this present study uses a human in vitro BBB model,
the hCMEC/D3 cell line. The hCMEC/D3 cell line is the most
promising immortalized human BBB cell line available today,
exhibiting many of the characteristics that are essential for a
good predictive BBB in vitro model (Poller et al., 2008; Weksler
et al., 2005). These include expression of tight junction proteins,
polarized expression of multiple ABC/SLC transporters and re-
strictive permeability (Dauchy et al., 2009; Tai et al., 2009b).
The following study is the first to investigate nifurtimox trans-
port interactions in a humanmodel of the BBB.2. Results
2.1. hCMEC/D3 — expression of endothelial cell marker
von Willebrand factor
We confirmed the endothelial cell phenotype by staining
monolayers of cells grown on collagen-coated coverslips for
vascular endothelial marker, von Willebrand factor (vWF)
(Fig. 1).
2.2. Influence of self-inhibition on
[3H]nifurtimox accumulation
By varying the concentrations of unlabelled nifurtimox in ac-
cumulation buffer alongside [3H]nifurtimox and [14C]sucrose,
we were able to assess any roles played by major BBB trans-
port proteins in the transport and subsequent accumulation
of [3H]nifurtimox and [14C]sucrose, compared to appropriate
controls. Accumulation of [3H]nifurtimox was not significant-
ly affected by the addition of unlabelled nifurtimox at a clini-
cally relevant dose of 6 μM or an increased dose of 12 μM
(Fig. 2). The addition of 60 μM and 150 μM unlabelled nifurti-
mox, however, caused significant increases in [3H]nifurtimox
accumulation at all time points (p<0.001) compared to DMSO
[3H]nifurtimox controls.
2.3. Roles of P-gp and BCRP in
[3H]nifurtimox accumulation
To assess any roles played by major BBB transport proteins in
the transport and subsequent accumulation of [3H]nifurtimox
and [14C]sucrose, a variety of drugs were used individually in
the accumulation buffer alongside [3H]nifurtimox and [14C]su-
crose and compared to appropriate controls. The influences of
P-gp and BCRP in the transport of [3H]nifurtimox, were tested
Fig. 1 – Immunofluoresence of endothelial cell marker vWF
in hCMEC/D3 cells. vWF was stained in 4% formaldehyde
fixed hCMEC/D3 cells grown on rat-tail collagen type-1
coverslips, as described in Section 4.3 of the Experimental
procedures. Cell nuclei were counterstained with 1 μg/ml
DAPI. For negative staining, fluorescent secondary
antibodies alone were incubated with the cells, along with
DAPI (inset). Viewed 63× with oil emersion with a Zeiss
LSM700 confocal microscope and images analysed with
Zen 2009 software.
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the functions of these transport proteins (Table 1). For P-gp as-
sessment we used haloperidol (40 μM) and dexamethasoneFig. 2 – Influence of self-inhibition on [3H]nifurtimox
accumulation. Unlabelled nifurtimox was added to
accumulation buffer in the ranges of 6 μM–150 μM in
0.05% DMSO to view the impact of self-inhibition on the
accumulation of [3H]nifurtimox in confluent monolayers
of hCMEC/D3 cells in 96 well plates. At concentrations of
6 μM and 12 μM, unlabelled nifurtimox caused no change
in accumulation of [3H]nifurtimox, but at concentrations
of 60 μM and 150 μM, a highly significant increase in [3H]
nifurtimox accumulation compared to controls was
observed at all time points (***p<0.001). All data
expressed as mean±S.E.M, n=4–6 (plates), with 6
replicates (wells) per plate Data were analyzed with
SigmaPlot 11.0.(200 μM) and for BCRP, ko143 (1 μM) and pheophorbide A
(PhA) (1 μM). The results showed that the P-gp acting drugs,
haloperidol and dexamethasone, had no affect on [3H]nifurti-
mox accumulation (Fig. 3A), whereas significant increases in
[3H]nifurtimox accumulation were observed with the addition
of both the BCRP acting drugs, ko143 and PhA (both p<0.001
inhibitor against controls) (Fig. 3B).
To further assess roles played by ABC transporters in [3H]
nifurtimox accumulation, cellular ATP was depleted using
10mM 2-deoxy-D-glucose (2-DG, see Experimental procedures
Section 4.5). This resulted in a 76% depletion of intracellular
ATP compared to untreated controls (data not shown). This ef-
fectively increased the accumulation of [3H]nifurtimox in the
cells compared to controls at all time points. When comparing
the effect of ATP depletion to that of inhibiting P-gp transport
(Fig. 3A), there was a significant difference with ATP depletion
causing an increased [3H]nifurtimox accumulation when com-
pared with P-gp inhibition(p<0.01). In contrast, comparing the
effect of ATPdepletion to that of BCRP inhibition (Fig. 3B) showed
that these two treatments caused similar changes to [3H]nifurti-
mox accumulation after 1, 2.5, 5 and 20min, although it was
noted that after 30 minutes ATP depletion caused a significantly
greater increase (by 17–20%) in [3H]nifurtimox accumulation
(p<0.05). Therewereno significant differences in [14C]sucrose ac-
cumulation between any treatments (data not shown).
2.4. Roles of MRP, OATPs and OATs in
[3H]nifurtimox accumulation
Probenecid (350 μM)was used to assess any initial contributions
to [3H]nifurtimox and [14C]sucrose accumulation from proteins
separate to P-gp and BCRP; namely multi-drug resistance asso-
ciated proteins (MRP) 1 and 2, organic anion-transporting poly-
peptides (OATPs) and organic anion transporters (OATs)
(Table 1). Fig. 4 illustrates the time dependent effect of probene-
cid on [3H]nifurtimox accumulation. This was not matched by
the presence of 10 μM indomethacin, where no significant
change to [3H]nifurtimox was observed at any time point.
Taurocholic acid (TCA, 200 μM) and para-aminohippuric acid
(PAH, 500 μM) were then used to assess function of OATPs and
OATs respectively. The addition of TCA caused significant
changes in [3H]nifurtimox accumulation from 2.5 min (p<0.01)
and onwards when all three time-points showed significant in-
creases (p<0.001 Fig. 3), albeit less than those observedwith the
BCRP inhibitors. PAH caused no significant differences in accu-
mulation of [3H]nifurtimox at any time point. No significant dif-
ferences in [14C]sucrose accumulation between any treatments
were observed (data not shown).
2.5. Combination therapy and
[3H]nifurtimox accumulation
With CTs becoming the treatments of choice for HAT, the ef-
fect of their addition to the accumulation buffer was observed
on [3H]nifurtimox and [14C]sucrose accumulation. The accu-
mulation of [3H]nifurtimox in the hCMEC/D3s was not signifi-
cantly affected by unlabelled melarsoprol (30 μM), whereas
unlabelled pentamidine (10 μM) caused an increase at
2.5 min (p<0.01) and this was maintained onwards to 30 min
(p<0.001), in comparison to DMSO controls (Fig. 5A).
Table 1 – Transporter interacting drugs used in this study. All molecules were used in the presence of 0.05% DMSO and used
at the published concentration ranges where they affect transport activity.
Drug Concentration Transporters Source Reference
Dexamethasone 200 μM P-gp MP Biomedicals, UK (Mark and Waddell, 2006; Mason et al.,
2008; Ueda et al., 1992)
Haloperidol 40 μM P-gp Sigma, UK (Matsson et al., 2009)
Ko143 1 μM BCRP Tocris bioscience, UK (Matsson et al., 2009)
Pheophorbide A 1 μM BCRP MP Biomedicals, UK (Weiss et al., 2007)
Indomethacin 10 μM MRP1 Sigma, UK (Rosenbaum et al., 2005)
PAH 500 μM OATs Acros organics, UK (Gibbs and Thomas, 2002; Sauer et al.,
2010; Sugiyama et al., 2001)
Probenecid 350 μM MRP-1, MRP-2, OATs, OATPs Sigma, UK (Gibbs and Thomas, 2002; Jorgensen et al.,
2007; Potschka et al., 2004)
TCA 200 μM OATPs Acros organics, UK (Gibbs and Thomas, 2002; Sugiyama et al., 2001)
PAH — para-aminohippuric acid, TCA — taurocholic acid.
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the accumulation of [3H]nifurtimox (without the presence of
DMSO) saw no significant changes arise (Fig. 5B). There were
nosignificant differences in [14C]sucrose accumulation between
any of these treatments, or between DMSO and no DMSO con-
trols (both [3H]nifurtimox and [14C]sucrose, data not shown).
2.6. Cytotoxicity of compounds used
The potential of the compounds used in this study to cause
cytotoxicity was assessed using an MTT assay and the effect
compared to untreated control endothelial cells (hCMEC/D3)
(Fig. 6). There were no significant differences on cell viability
after 30 minutes exposure to the drugs, except when using
the positive control 1% Triton X-100 (p<0.01).
2.7. BCRP and P-gp protein expression in hCMEC/D3s
Mouse anti-human BCRP/ABCG2 and mouse anti-human P-gp/
MDR1 monoclonal antibodies were used to detect protein ex-
pression of BCRP and P-gp in this cell system using SDS-PAGE
andWestern blotting. Bands detected at the expectedmolecular
weights of 70 kDa for BCRP and 170 kDa for P-gp confirmed their
expression using SDS-PAGE andWestern blot analysis (Figs. 7A
and B). HepG2 cell lysates were used as positive controls
(Vander Borght et al., 2008; Wojtal et al., 2006).3. Discussion
Human African trypanosomiasis has a huge impact, both so-
cial and economic, on affected sub-Saharan communities. It
requires constant surveillance and careful implementation
of preventative measures by the authorities to successfully
combat the disease. Collapses of disease surveillance and
changes in political agenda have allowed HAT's prevalence
to increase and this is one of the reasons the disease has not
been eradicated. Another reason is due to the unsatisfactory
treatment of the disease due to the fact that the anti-HAT
drugs available are expensive, can be extremely difficult to
successfully administer, have limited efficacy and can cause
severe adverse reactions. These features combined with alack of understanding about anti-HAT drugs highlight the
need for more research into the treatment of this disease.
The aim of this study was to investigate whether BBB
transport proteins were being utilized by the emerging drug
of choice for treating HAT, nifurtimox, and also investigated
the effects, if any, of anti-HAT CT on its delivery. We used
the hCMEC/D3 cell line as an in vitro model of the human
BBB, first confirming an endothelium phenotype through
staining for vWF. We then investigated the effect of unla-
belled nifurtimox on [3H[nifurtimox accumulation and whilst
the lower concentrations (6 and 12 μM) caused no significant
change, the higher concentrations (60 μM and 150 μM) saw a
large increase in [3H]nifurtimox accumulation illustrating
that nifurtimox is a substrate for an efflux transporter in this
human BBB model. Our group has previously shown that
nifurtimox is a substrate for an efflux protein at the murine
BBB, which is unlikely to be P-gp, as shown by the use of P-
gp deficient animals (Jeganathan et al., 2011). P-gp is
expressed at the luminal membrane of the human BBB and
removes a wide variety of substrates from the endothelial
cell cytoplasm. The lack of interaction between nifurtimox
and P-gp was also evident in the hCMEC/D3s through the
use of the P-gp substrate, dexamethasone, and the specific
P-gp inhibitor (at 40 μM), haloperidol, which did not cause
any significant differences in [3H]nifurtimox accumulation
over the 30 minute incubation period. However, a promising
potential efflux transporter for nifurtimox was suggested in
our earlier animal study (Jeganathan et al., 2011). Further in-
vestigation in the hCMEC/D3s confirmed this efflux transport-
er to be BCRP with both the BCRP substrate, PhA, and the BCRP
specific inhibitor (used in the range of 0.1–1 μM), ko143, caus-
ing large increases in [3H]nifurtimox accumulation. Impor-
tantly, the increase in [3H]nifurtimox accumulation caused
by these BCRP modulators is in line with that seen with 60–
120 μM unlabelled nifurtimox. BCRP, like P-gp, is expressed
luminally at the BBB and both these proteins are members of
the ABC transporter superfamily which play key physiological
roles in protecting tissues from toxic xenobiotics and other
potentially harmful endogenous metabolites. ABC trans-
porters require energy in the form of ATP to pump drugs out
of the brain against concentration gradients. This ABC-
transporter dependence on ATP was exploited here when we
Fig. 3 – The effects of P-gp and BCRP on [3H]nifurtimox
accumulation. To assess the roles played by the ABC
transporters, P-gp and BCRP, in the transport of
nifurtimox, the accumulation of [3H]nifurtimox in
confluent monolayers of hCMEC/D3 cells in 96 well plates
was observed, with or without known transporter
interacting drugs, in the presence of 0.05% DMSO. The
P-gp substrate and inhibitor (dexamethasone and
haloperidol respectively) caused no significant alteration
in the accumulation of [3H]nifurtimox. ATP depletion
caused a significant increase at all time points compared to
both control data andP-gp inhibition (A). PhAandko143 (aBCRP
substrate and BCRP inhibitor respectively), caused a significant
increase in [3H]nifurtimox accumulation in the cells compared
to control data (***p<0.001). The values were comparable to
those generated by ATP depletion which also caused a
significant increase compared to controls at all time points
(**p<0.01, ***p<0.001) until the 30minute time point when ATP
depletion caused a significant increase in accumulation
compared to both inhibitors (*p<0.05) (B). All data expressed as
mean±S.E.M, n=4–6 (plates), with 6 replicates (wells) per plate.
Data were analyzed with SigmaPlot 11.0.
Fig. 4 – The effects of OATs, OATPs andMRPs on [3H]nifurtimox
accumulation. To assess the roles played by members of the
transport families OATs, OATPs and MRPs in the transport of
nifurtimox, the accumulation of [3H]nifurtimox in confluent
monolayers of hCMEC/D3 cells in 96 well plates was observed,
with or without known transporter interacting drugs, in the
presence of 0.05% DMSO. The OAT interacting drug, PAH and
theMRP1 interacting drug, indomethacin, causedno significant
changes in the accumulation of [3H]nifurtimox. From 2.5
minutes onwards, both probenecid (OATs, OATPs and MRPs)
and TCA (OATPs) caused significant increases in the
accumulation (**p<0.01, ***p<0.001). Data were analyzed with
SigmaPlot 11.0. All data expressed as means±S.E.M, n=4–6
(plates), with 6 replicates (wells) per plate. Data were analyzed
with SigmaPlot 11.0.
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established inhibitor 2-DG (Wang et al., 2011; Whiteman et al.,
2002). ATP depletion resulted in accumulation values compara-
ble to those generatedwithBCRP inhibitors butnotwith P-gp in-
hibitors. At the 30minute stage, accumulation of [3H]nifurtimox
using BCRP inhibitors was approximately 83% of theaccumulation produced by ATP depletion. These increases in
[3H]nifurtimox accumulation induced by ATP depletion further
supports the evidence that P-gp does not have a role in nifurti-
mox transport, but BCRPplays a crucial one. The protein expres-
sion of both P-gp and BCRPwas confirmed in the hCMEC/D3s by
Western blot, which is consistent with the findings of several
other groups (Poller et al., 2008; Tai et al., 2009a; Weksler et al.,
2005). These data suggest that not only is BCRP functional in
the hCMEC/D3s but perhaps inhibiting BCRP could improve
the delivery and efficacy of nifurtimox. Indeed, that nifurtimox
could be a substrate for BCRP that has beenpreviously indicated
(Garcia-Bournissen et al., 2010; Jeganathan et al., 2011). In their
study investigating nifurtimox transfer in breast milk, Garcia-
Bournissen et al. suggested that as the antibiotic, nitrofuran-
toin, is structurally related to nifurtimox and is a substrate for
BCRP (Merino et al., 2005), perhaps nifurtimox may also be a
substrate (Garcia-Bournissen et al., 2010). The findings of our
study provide direct evidence of this hypothesis for the first
time in a human in vitro BBB model.
To further investigate the roles of other transport systems
with nifurtimox, a variety of other drugs were used to affect
transport activity of MRPs, OATs and/or OATPs. MRPs, other
members of the ABC transporter superfamily that also mediate
brain-to-blood efflux, play important roles in vivo to protect the
brain from xenobiotics. OATs and OATPs are membrane trans-
port proteins that play large roles in the transport of endoge-
nous molecules across cell membranes. MRP1 expression has
previously been shown in the hCMEC/D3s at mRNA (Carl et al.,
2010) and protein levels (Weksler et al., 2005). The expression
Fig. 5 – Combination therapy and its effect on accumulation of
[3H]nifurtimox. Other anti-HAT drugs were added with [3H]
nifurtimox in the accumulation buffer to assess their impact on
accumulation. Unlabelled melarsoprol caused no significant
change, but pentamidine induced a significant increase in
accumulation of [3H]nifurtimox, from 2.5 minutes onwards
(**p<0.01, ***p<0.001) (A, DMSO present). Neither unlabelled
suramin nor eflornithine caused a significant change in the
accumulation of [3H]nifurtimox (B, DMSO absent). Data were
analyzed with SigmaPlot 11.0. All data expressed as means±
S.E.M, n=6 (plates) per graph,with 6 replicates (wells) per plate.
Data were analyzed with SigmaPlot 11.0.
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shown at mRNA level only in the hCMEC/D3s (Carl et al., 2010;
Poller et al., 2008), and they are also expressed in the human
brain (Gibbs and Thomas, 2002). However, to date neither pro-
tein nor mRNA expression of the OAT superfamily in the
hCMEC/D3 cell line has been demonstrated. The data here com-
ply with this knowledge somewhat, suggesting that nifurtimox
appears to be a substrate of functional OATP systems, but OATs
andMRP1 appear not to be involved. This was demonstrated by
use of the broad spectrum MRP, OAT and OATP inhibitor, pro-
benecid; the MRP1 inhibitor, indomethacin, the OATP competi-
tive inhibitor; TCA and the OAT competitive inhibitor, PAH.
OATPs are bidirectional drug transporters (Nozawa et al., 2005)
and the increases in accumulation with the addition of TCA
could provide some evidence for their role in nifurtimoxtransport. However, although indomethacin is commonly
used as a MRP1 inhibitor, it has also been shown to be a sub-
strate of OATPs and OATs, albeit at different concentration
ranges than used here (Parepally et al., 2006). Notably the
changes in [3H]nifurtimox accumulation were much smaller
than those seenwith the BCRP specific drugs and accumulation
following ATP depletion, suggesting only minor roles for OATPs
in comparison to the role played by BCRP. It is also important to
point out that some groups have found that probenecid is a
BCRP substrate in vitro, and this is also a possible explanation
for the increase in [3H]nifurtimox accumulation using this
drug (Merino et al., 2006). However, other groups have found
no such evidence of BCRP/probenecid interaction (Pan et al.,
2007). It has also been reported that neither TCA (Suzuki et al.,
2003) nor indomethacin (Elahian et al., 2010) interacts with
BCRP. The concentrations of drugs used in this studywere care-
fully chosen to follow those used in previous in vivo studies by
our group, to be in line with the clinically relevant doses used
in the field (with the anti-HAT drugs) and to be in line with
those reported in publications such as Matsson et al. 2009.
These data and findings by other groups highlight that drugs af-
fecting transport activity must be used at specific concentra-
tions to affect the targeted transport proteins.
With combination therapy becoming the most promising
method of clinical S2 HAT treatment, we also investigated
whether other unlabelled anti-HAT drugs could modulate
the accumulation of [3H]nifurtimox in human brain endothe-
lium. In line with previous work by our group, an increase in
[3H]nifurtimox accumulation was seen with the addition of
10 μM pentamidine. Pentamidine, a S1 acting drug, has been
previously shown by our group to be a substrate for P-gp and
is also transported by other transport proteins including
MRP. This present study with P-gp inhibitors suggests that
perhaps nifurtimox also interacts with other membrane
transporters. BCRP andmembers of the OATPs could be candi-
dates as indicated by their interactions with PhA, ko143, pro-
benecid and PAH. However, no other drugs from the CT
experiments, including eflornithine, caused any significant
changes in [3H]nifurtimox accumulation in the cells, which
contradicts our previous findings that eflornithine, suramin
and melarsoprol caused decreases in the brain distribution
of [3H]nifurtimox in vivo (Jeganathan et al., 2011). One must
of course be careful when comparing in vivo brain distribution
and in vitro endothelial cell accumulation data. When observ-
ing the in vivo BBB endothelial cell pellet analysis for [3H]pent-
amidine previously published by our group, it was evident
that the drug accumulated in the cells (Sanderson et al.,
2009). [3H]nifurtimox also accumulated in vivo in BBB endothe-
lial cell pellets, and the effect on accumulation with CT were
similar to those reported here with an increase observed
with the addition of unlabelled pentamidine and little or no
difference with the other drugs (Jeganathan et al., 2011). The
reasoning behind the improved cure rates of patients using
NECT compared to eflornithine alone, based on our results,
is unlikely to be due to the interactions of the drugs with
membrane transporters at the level of the brain capillary en-
dothelium. It has been stipulated that the arrestment of para-
site defences caused by eflornithine allows the efficacy of
nifurtimox to be improved and perhaps this is the main rea-
son behind NECT success (Priotto et al., 2009).
Fig. 6 – Cytotoxic effects of compounds used in the study. The test compounds were assessed for any cytotoxic effects using an
MTT assay during 30minute incubations with confluent monolayers of hCMEC/D3 cells in 96 well plates, as described in
Section 4.7 of Experimental procedures. The results are expressed as percentage viability±S.E.M and compared to control
untreated cells, which were incubated for 30 min in normal medium (Section 4.2). None of the compounds induced a significant
change in cell viability, except for the positive control, 1% Triton x-100 (**p<0.01). Data were analyzed with SigmaPlot 11.0 with
n=3 (plates), 4 replicates per n (4 wells).
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mains unknown. It is likely that the lipophilic properties of
nifurtimox (with an octanol–saline partition coefficient of
5.46 Jeganathan et al., 2011) allow it to cross cell membranes
by passive diffusion and previous work has shown that it
not only appears to use a transcellular route of entry, but en-
ters the mouse brain at sufficient amounts to be effective in
killing trypanosomes (Jeganathan et al., 2011). However, the
role played, if any, by blood-to-brain transporters remains
elusive. Any effect that the drugs had on the expression of
transporters in the hCMEC/D3 cell line has not been assessed
here. It has been shown previously that some drugs can upre-
gulate functional expression of drug transporters such as P-
gp, and this is well documented with dexamethasone
(Narang et al., 2008), but the 30 minute time frames of the ex-
periments in this report were unlikely to be sufficient at in-
ducing any significant increase in expression or activity.
Studying nifurtimox entry and exit to the brain is crucial to
improving treatment of second stage HAT, especially now
that NECT is fast becoming the treatment of choice. Consider-
ing the current usage of NECT, it is somewhat surprising thatFig. 7 – Expression of P-gp and BCRP in the hCMEC/D3 cells.
Confluentmonolayers of hCMEC/D3s and flasks of HepG2 cells
were lysed in TGN buffer and the expression of P-gp (A) and
BCRP (B) was analysed using western blotting, as described in
Section 4.8 of the Experimental procedure. GAPDHwas stained
as a loading control.very little is known about the mechanisms being used by
these drugs to gain entry to the human brain. We report
here that nifurtimox is a substrate of BCRP and possibly, to a
lesser extent, members of the OATP transport family, in an
in vitro model of the BBB. We also report that, with regards to
the combination therapy approach to treating HAT, the com-
bination of clinically relevant doses of eflornithine and nifur-
timox does not appear to hamper entry of nifurtimox into the
BBB and the reasoning behind its success in the field is unlike-
ly due to transporter interactions at the BBB. In addition, our
data suggests that pentamidine could actually improve the
delivery of nifurtimox, which is in line with previous work
by our group in an animal model.4. Experimental procedure
4.1. Materials
Nifurtimox (MW 287.30) was custom labelled with tritium (3H 3,4
furamring) specific activity: 2 Ci/mmol) byMoravekBiochemicals
(California, USA). [14C]sucrose (4980mCi/mmol) was purchased
from Moravek Biochemicals. Unlabelled suramin, eflornithine
and pentamidine isethionate sodium salt were purchased from
Sigma Chemical Company (Dorset, UK). Unlabelled nifurtimox
andmelarsoprol were a kind gift from Professor S. Croft (London
School of Hygiene and Tropical Medicine, UK). Probenecid, indo-
methacin and dimethyl sulfoxide (DMSO) were purchased from
Sigma Chemical Company. Dexamethasone and Pheophorbide
A (PhA) were purchased from Acros Organics, (Fisher Scientific,
Loughborough, UK). Para-aminohippuric acid (PAH) and tauro-
cholic acid (TCA) were purchased from MP Biochemicals, UK.
Ko143 and haloperidol were purchased from Tocris Bioscience
(Bristol, UK) and Sigma, respectively. The hCMEC/D3 cell line
was obtained from Professor Pierre O. Couraud (Institut Cochin,
Université Paris Descartes, CNRS, Paris, France) and Dr Ignacio
Romero (The Open University, Department of Life Sciences,
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purchased from Lonza (Basel, Switzerland). All cultureware was
Nunclon brand and purchased from Thermo Scientific, UK. Rat
tail collagen 1 and penicillin-streptomycin were purchased from
Gibco, Invitrogen, (Paisley, UK). HEPES 1M was purchased from
Sigma Chemical Company. Primary mouse anti-P-gp/MDR1
[C219] (ab3364), anti-BCRP/ABCG2 [BXP-21] (ab3380) and mouse
anti-GAPDH monoclonal antibodies [6C5] (ab8245), rabbit poly-
clonal secondary antibody (HRP) (ab6728) were purchased from
Abcam, Cambridge, UK. Goat anti-rabbit Alexa Fluor 488was pur-
chased from Invitrogen, UK. HepG2 cells were a kind gift fromMr
Enrico Cristante (Imperial College London, UK). Rabbit anti-
human von Williebrand factor (vWF) (P0226, Dako, Stockport,
UK) was a kind gift from Dr Sarah Chapple (King's College
London).
4.2. Cell culture
ThehCMEC/D3swere cultured in EBM-2 endothelial growthme-
dium supplemented with HEPES, penicillin–streptomycin, 2.5%
foetal bovine serum (FBS), insulin-like growth factor-1, vascular
endothelial growth factor, epidermal growth factor, hydrocorti-
sone and basic fibroblast growth factor from the EGM-2MV Bul-
letKit as previously described (Poller et al., 2008). All cells used in
the experiments were seeded at a density of 2.5×104 cells/cm2
and were between passages 28 and 35. Before seeding, cells
were checked for viability by 0.4%TrypanBlue solution in a hae-
mocytometer. Cultureware was coated with 0.1 mg/ml rat tail
collagen type 1 for 2 h at 37 °C prior to seeding. Cells were cul-
tured in an incubator with a saturated humidity at 37 °C in 5%
CO2 and 95% fresh air and grown to 80–90% confluency before
seeding (after 3 days). For experiments, cells were grown to
100% confluency (whichwas reached at 4 days) in collagen coat-
ed 96 well plates and then left for a further 3 days until experi-
ments (7 days after seeding). Medium was changed every
2–3 days. Protein expression (BCA® protein assay, Thermo Sci-
entific, Loughborough, UK) and integrity of plasmamembranes
([14C]sucrose) were monitored to confirm cell viability and used
for correction factors (see experimental details below). HepG2
cells were cultured in 25 cm2 flasks in Dulbecco's modified
Eagle's medium (DMEM, Gibco, Invitrogen) with 10% FBS (PAA,
Yeovil, A15-151).
4.3. Staining of vWF
The endothelial phenotype of the hCMEC/D3s was first con-
firmed by staining for endothelial cell marker vWF (Fig. 1)
(Schram et al., 2003). Cells were grown on rat-tail collagen
type 1 coated glass coverslips and then fixed using 4% formal-
dehyde in PBS for 10 min at 4 °C. The coverslips were then
washed three times with PBS and treated for 5 min with 0.1%
Triton X-100 in PBS at room temperature (RT). Following this
permeablisation step, coverslips were washed three times in
PBS and then non-specific sites were blocked with PBS con-
taining 10% serum, 0.1% Triton X-100 for 30 min at RT. The
coverslips were then incubated overnight at 4 °C with primary
antibody (1:200 for rabbit anti-human vWF in PBS). Following
overnight incubation, coverslips were washed three times
with PBS and goat anti-rabbit Alexa Fluor 488 (1:200 in PBS)
was added for 1 h at RT. Following secondary incubation,coverslips were washed in PBS twice, and incubated in PBS
containing 1 μg/ml DAPI nucleus stain (New England Biolabs,
Bristol, UK) for 30 min at RT. Coverslips were then washed a
final time in PBS, dipped in distilled water and mounted
onto slides with PVA-DABCO®, before viewing with a Zeiss
LSM710 confocal microscope and image analysis software
Zen 2009 (Zeiss, Germany).
4.4. Drug accumulation assays
Drug accumulation experiments were performed on confluent
monolayers of hCMEC/D3s, grown in the centre 60 wells of 96
well plates. Accumulation studies are based on a previous
study (Chishty et al., 2004). Medium was removed from wells
and replaced with a 200 μl aliquot of [3H]nifurtimox (120nM)
and [14C]sucrose (972 nM) in accumulation buffer (consisting of
135mM NaCl, 10mM HEPES, 5.4 mM KCL, 1.5 mM CaCl2,
1.2 mM MgCl2, 1.1 mM D-glucose, and distilled water, pH 7.4).
Columns of wells (6 wells/column, 10 columns/plate) were ex-
posed to the [3H]drug/[14C]drug/buffer mix at five different
time periods (1, 2.5, 5, 20 and 30min). This allowed assessment
of drug accumulation in the cells. The accumulation assays
were performed on a temperature-controlled shaker (THERMO-
star, BMG labtech, Offenburg, Germany) at 37 °C and 120 rpm.
Once each column of cells had been exposed for the correct
amount of time, the wells were washed 3 times with ice-cold
phosphate buffered saline (1× PBS, Gibco, Invitrogen, UK) to
stop transport processes and remove drugs and buffer that
had not accumulated in the cells. The cells were then lysed by
adding 200 μl of 1% Triton x-100 (Sigma, UK) per well for 1 h at
37 °C to liberate any accumulated radiolabelled drug and solubi-
lise the cell proteins. 100 μl of eachwell was then added to scin-
tillation vial alongwith 4 ml scintillation fluid (OptiphaseHisafe
2, PerkinElmer, UK) added and samples counted as described
previously (Sanderson et al., 2008). The remaining 100 μl in
each well was used to perform a BCA™ protein assay, using bo-
vine serumalbumin as standards, andmeasured spectrophoto-
metrically on a Labsystems Multiscan reader with Ascent
software. Total accumulation of [3H]nifurtimox was calculated
as the sum of accumulation and efflux and termed the volume
of distribution (Vd). Vd is derived from the ratio of dpm/mg pro-
tein to dpm/μl buffer. The Vd values for [3H]nifurtimoxwere cor-
rected with the Vd values for [14C]sucrose which is a marker of
non-specific binding and extracellular space.
4.5. Transporter inhibition assays
To study the transport mechanisms being utilized by nifurti-
mox, a range of unlabelled nifurtimox concentrations in the
presence of 0.05% dimethyl sulfoxide (DMSO) (6 μM, 12 μM,
60 μM and 150 μM) were also used alongside [3H]nifurtimox
and [14C]sucrose in the accumulation buffer to assess the effect
on [3H]nifurtimox efflux from the cells. We also used a series of
established transporter interacting (substrates and inhibitors)
drugs were used alongside [3H]nifurtimox and [14C]sucrose in
accumulation buffer. The impact of these drugs on [3H]nifurti-
mox and [14C]sucrose accumulation in the cells was assessed
at 1, 2.5, 5, 20 and 30min. Haloperidol (40 μM), ko143 (1 μM), in-
domethacin (10 μM) pheophorbide A (PhA) (1 μM), taurocholic
acid (TCA) (200 μM), para-aminohippuric acid (PAH) (500 μM),
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accumulation buffer in 0.05% DMSO in individual experiments
to inhibit different transport systems (Table 1).
To further assess the impact of ABC-transporters on the ac-
cumulation of [3H]nifurtimox, cells were depleted of ATP by in-
cubating them for 1 h in glucose-free DMEM containing 10mM
2-deoxy-D-glucose (2-DG, Sigma), and cellular ATP was deter-
mined using the Promega Enliten® ATP Assay System kit (Pro-
mega, Southampton, UK). Briefly, cells were grown in 24 well
plates for 7 days before their medium was removed, washed
twice with warm glucose free DMEM (Gibco, Invitrogen) and in-
cubated for 1 h in glucose-free DMEM containing 10 mM 2-DG
which is a well documented inhibitor of glycolysis and results
in a decrease in intracellular ATP in vitro (Wang et al., 2011).
After this incubation step, the 2-DG solution was removed and
cells were incubated in 100 μl of 2% trichloroacetic acid (TCA,
Sigma) in glucose-free DMEM, also containing 0.002% xylenol
blue dye (a pHcolour indicator, Sigma) at RT for 10 min following
the manufacturer's direction. TCA both depletes cellular ATP
and inhibits enzymes that degrade ATP (Whiteman et al.,
2002). As TCA also inhibits the downstreamassay, itwas neutra-
lised with Tris-acetate (pH 7.75) to bring the total TCA percent-
age to 0.1% following the manufacturer's direction. Samples
were then taken and addedwith the reconstituted luciferase/lu-
ciferin reagent mix from the kit in a sterile white 96-well plate
(Nunc) and theATP luminescence determined in a Biotek Syner-
gyHT luminometer using KC4 software and compared to control
cells not treatedwith 2-DG. For accumulation, cells were treated
with 10mM 2-DG before incubation with [3H]nifurtimox as de-
scribed above.
4.6. Combination therapy accumulation
In a series of experiments to assess the impact of CT on [3H]
nifurtimox cellular accumulation, the clinically relevant concen-
trations of melarsoprol (30 μM), pentamidine (10 μM), suramin
(150 μM) or eflornithine (250 μM) were added to accumulation
buffer. DMSOwasused to dissolvemelarsoprol and pentamidine
to give a final concentrationof 0.05%DMSO.Control experiments
here also contained 0.05%DMSO. For unlabelled eflornithine and
suraminand the appropriate controls, noDMSOwasused. There
wasno significant difference betweenaccumulation of [3H]nifur-
timox with or without 0.05% DMSO (data not shown).
4.7. MTT assay
The cytotoxic effects of the drugs used in this study were
assessed on confluent monolayers of cells in 96 well plates
using an MTT assay. Cells underwent 30 minute incubations
with a 200 μl/well aliquot of each drug in accumulation buffer
at the concentrations used in the experiments. After 30 min,
the buffer was aspirated and replaced with a 100 μl aliquot of
1 mg/ml MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetra-
zolium bromide, Sigma, UK) in DMEM without phenol red
(Gibco, Invitrogen, UK). The cells were then incubated for 4 h
at 37 °C, the solution removed and replaced with 100 μl
propan-2-ol per well, and the absorbance was measured. Ab-
sorbance values were corrected by protein content (deter-
mined using a BCA assay) and expressed as percentage
viability compared to control untreated cells.4.8. SDS-PAGE and Western blot
The expression of P-gp and BCRP by the hCMEC/D3 and HepG2
cell lines was analysed by Western blot using Abcam primary
mouse anti-P-gp/MDR1 [C219] (ab3364) and mouse anti-BCRP/
ABCG2 [BXP-21] (ab3380) monoclonal antibodies at 1:80 and
1:1000 dilutions in PBS-Tween (PBS-T, PBS with 0.05% Tween
20) with 0.5% BSA, (Sigma) respectively. Mouse anti-GAPDH
monoclonal antibody [6C5] (ab8245), was used as a loading con-
trol, 1:1000 in PBS-T with 0.5% BSA. Confluent monolayers of
hCMEC/D3 cells and flasks of HepG2 cells (positive controls)
were lysed in TGN lysis buffer (50 mM Tris, 150 mM NaCl, 10%
glycerol, 50 mM glycerophosphate B, 1% Tween-20, 0.2% NP-40,
all purchased from Sigma, UK), and 25 μg loaded per lane. For
P-gp, a precast 4–20% gradient gel was used (Bio-Rad Europe,
456-1093S). For BCRP, a 10%SDS-PAGE acrylamide/bisacrylamide
gel was used. Following electrophoresis, proteins were trans-
ferred using semi-dry transfer onto methanol activated
Immobilon-P PVDFmembranes (0.45 μMpore size, Millipore, Ire-
land), blocked for 2 h at RT in PBS-Twith 5%milk powder and in-
cubated overnight at 4 °C with antibody. Membranes were then
washed 3× with PBS-T and incubated for 1 h at RT with rabbit
anti-mouse HRP conjugated secondary antibody 1:2000 in PBS-
T (Abcam, ab6728), before visualizationwith enhanced chemilu-
minescence (ECL,Thermo Scientific, 32209) in a dark room.
4.9. Statistical analysis
Comparisons were made between control plates of cells and dif-
ferences at the 5% level considered significant. Multiple-time ac-
cumulation data were analysed by TwoWay RepeatedMeasures
ANOVA tests and Holm–Sidak posthoc tests, MTT assay data
were compared against controls using a One Way ANOVA using
Sigma Plot version 11.0 software (SPSS Science Software UK
Ltd., Birmingham UK). All data are expressed as mean±SEM, ex-
cept MTT data which are expressed as percentage viability.Conflict of interest
The authors acknowledge that there are no conflicts of interest.Acknowledgments
The authors would like to thank Professor Pierre Couraud and Dr
Ignacio Romero for the hCMEC/D3 cell line and Mr Enrico Cris-
tante (Imperial College London) for the HepG2 cell line. We
would also like to thank Dr Jonathan Corcoran and Dr Maria de
Castro Vasconcelos Goncalves (King's College London) for their
help with the confocal microscopy. This work was supported by
theWellcomeTrust [080268] andanEPSRCDTgrant (EP503523/1).R E F E R E N C E S
Abbott, N.J., Ronnback, L., Hansson, E., 2006. Astrocyte–endothelial
interactions at the blood–brain barrier. Nat. Rev.Neurosci. 7, 41–53.
120 B R A I N R E S E A R C H 1 4 3 6 ( 2 0 1 2 ) 1 1 1 – 1 2 1Bouteille, B., Oukem, O., Bisser, S., Dumas, M., 2003. Treatment
perspectives for human African trypanosomiasis. Fundam.
Clin. Pharmacol. 17, 171–181.
Brun, R., Blum, J., Chappuis, F., Burri, C., 2010. Human African
trypanosomiasis. Lancet 375, 148–159.
Carl, S.M., Lindley, D.J., Couraud, P.O., Weksler, B.B., Romero, I.,
Mowery, S.A., Knipp, G.T., 2010. ABC and SLC transporter
expression and pot substrate characterization across the
human CMEC/D3 blood–brain barrier cell line. Mol. Pharm. 7,
1057–1068.
Checchi, F., Piola, P., Ayikoru, H., Thomas, F., Legros, D., Priotto, G.,
2007. Nifurtimox plus Eflornithine for late-stage sleeping
sickness in Uganda: a case series. PLoS Negl. Trop. Dis. 1, e64.
Chishty, M., Begley, D.J., Abbott, N.J., Reichel, A., 2004. Interaction
of nucleoside analogues with nucleoside transporters in rat
brain endothelial cells. J. Drug Target. 12, 265–272.
Dauchy, S., Miller, F., Couraud, P.O., Weaver, R.J., Weksler, B.,
Romero, I.A., Scherrmann, J.M., De Waziers, I., Decleves, X.,
2009. Expression and transcriptional regulation of ABC
transporters and cytochromes P450 in hCMEC/D3 human
cerebral microvascular endothelial cells. Biochem. Pharmacol.
77, 897–909.
Elahian, F., Kalalinia, F., Behravan, J., 2010. Evaluation of
indomethacin and dexamethasone effects on BCRP-mediated
drug resistance in MCF-7 parental and resistant cell lines. Drug
Chem. Toxicol. 33, 113–119.
Garcia-Bournissen, F., Altcheh, J., Panchaud, A., Ito, S., 2010. Is use
of nifurtimox for the treatment of Chagas disease compatible
with breast feeding? A population pharmacokinetics analysis.
Arch. Dis. Child. 95, 224–228.
Gibbs, J.E., Thomas, S.A., 2002. The distribution of the anti-HIV
drug, 2′3′-dideoxycytidine (ddC), across the blood–brain and
blood-cerebrospinal fluid barriers and the influence of organic
anion transport inhibitors. J. Neurochem. 80, 392–404.
Gonnert, R., Bock, M., 1972. The effect of nifurtimox on
Trypanosoma cruzi in tissue cultures. Arzneimittelforschung 22,
1582–1586.
Haberkorn, A., 1979. The effect of nifurtimox on experimental
infections with trypanosomatidae other than Trypanosoma
cruzi. Zentralbl. Bakteriol. Orig. A 244, 331–338.
Haberkorn, A., Gonnert, R., 1972. Animal experimental
investigation into the activity of nifurtimox against
Trypanosoma cruzi. Arzneimittelforschung 22, 1570–1582.
Jeganathan, S., Sanderson, L., Dogruel, M., Rodgers, J., Croft, S.,
Thomas, S.A., 2011. The distribution of nifurtimox across the
healthy and trypanosome-infected murine blood–brain and
blood-CSF barriers. J. Pharmacol. Exp. Ther. 336, 506–515.
Jorgensen, L., Van Beek, J., Lund, S., Schousboe, A., Badolo, L., 2007.
Evidence of Oatp and Mdr1 in cryopreserved rat hepatocytes.
Eur. J. Pharm. Sci. 30, 181–189.
Kristensson, K., Nygard, M., Bertini, G., Bentivoglio, M., 2010.
African trypanosome infections of the nervous system:
parasite entry and effects on sleep and synaptic functions.
Prog. Neurobiol. 91, 152–171.
Lutje, V., Seixas, J., Kennedy, A., 2010. Chemotherapy for second-stage
Human African trypanosomiasis. Cochrane Database Syst. Rev. 8,
CD006201.
Mark, P.J., Waddell, B.J., 2006. P-glycoprotein restricts access of
cortisol and dexamethasone to the glucocorticoid receptor in
placental BeWo cells. Endocrinology 147, 5147–5152.
Mason, B.L., Pariante, C.M., Thomas, S.A., 2008. A revised role for
P-glycoprotein in the brain distribution of dexamethasone,
cortisol, and corticosterone inwild-type andABCB1A/B-deficient
mice. Endocrinology 149, 5244–5253.
Matsson, P., Pedersen, J.M., Norinder, U., Bergstrom, C.A.,
Artursson, P., 2009. Identification of novel specific and general
inhibitors of the three major human ATP-binding cassette
transporters P-gp, BCRP and MRP2 among registered drugs.
Pharm. Res. 26, 1816–1831.Merino, G., Jonker, J.W., Wagenaar, E., Van Herwaarden, A.E.,
Schinkel, A.H., 2005. The breast cancer resistance protein
(BCRP/ABCG2) affects pharmacokinetics, hepatobiliary
excretion, and milk secretion of the antibiotic nitrofurantoin.
Mol. Pharmacol. 67, 1758–1764.
Merino, G., Alvarez, A.I., Pulido, M.M., Molina, A.J., Schinkel, A.H.,
Prieto, J.G., 2006. Breast cancer resistance protein (BCRP/ABCG2)
transports fluoroquinolone antibiotics and affects their oral
availability, pharmacokinetics, and milk secretion. Drug Metab.
Dispos. 34, 690–695.
Moens, F., DeWilde, M., Ngato, K., 1984. Clinical trial of nifurtimox
in human African trypanosomiasis. Ann. Soc. Belg. Med. Trop.
64, 37–43.
Narang, V.S., Fraga, C., Kumar, N., Shen, J., Throm, S., Stewart, C.F.,
Waters, C.M., 2008. Dexamethasone increases expression and
activity ofmultidrug resistance transporters at the rat blood–brain
barrier. Am. J. Physiol. Cell Physiol. 295, C440–C450.
Nozawa, T., Minami, H., Sugiura, S., Tsuji, A., Tamai, I., 2005. Role
of organic anion transporter OATP1B1 (OATP-C) in hepatic
uptake of irinotecan and its active metabolite, 7-ethyl-10-
hydroxycamptothecin: in vitro evidence and effect of single
nucleotide polymorphisms. Drug Metab. Dispos. 33, 434–439.
Pan, G., Giri, N., Elmquist, W.F., 2007. Abcg2/Bcrp1 mediates the
polarized transport of antiretroviral nucleosides abacavir and
zidovudine. Drug Metab. Dispos. 35, 1165–1173.
Parepally, J.M., Mandula, H., Smith, Q.R., 2006. Brain uptake of
nonsteroidal anti-inflammatory drugs: ibuprofen, flurbiprofen,
and indomethacin. Pharm. Res. 23, 873–881.
Poller, B., Gutmann, H., Krahenbuhl, S., Weksler, B., Romero, I.,
Couraud, P.O., Tuffin, G., Drewe, J., Huwyler, J., 2008. The
human brain endothelial cell line hCMEC/D3 as a human
blood–brain barrier model for drug transport studies. J.
Neurochem. 107, 1358–1368.
Potschka, H., Baltes, S., Loscher, W., 2004. Inhibition of multidrug
transporters by verapamil or probenecid does not alter
blood–brain barrier penetration of levetiracetam in rats.
Epilepsy Res. 58, 85–91.
Priotto, G., Kasparian, S., Ngouama, D., Ghorashian, S., Arnold, U.,
Ghabri, S., Karunakara, U., 2007. Nifurtimox-eflornithine
combination therapy for second-stage Trypanosoma brucei
gambiense sleeping sickness: a randomized clinical trial in
Congo. Clin. Infect. Dis. 45, 1435–1442.
Priotto, G., Kasparian, S., Mutombo, W., Ngouama, D., Ghorashian,
S., Arnold, U., Ghabri, S., Baudin, E., Buard, V., Kazadi-Kyanza, S.,
Ilunga, M., Mutangala,W., Pohlig, G., Schmid, C., Karunakara, U.,
Torreele, E., Kande, V., 2009. Nifurtimox–eflornithine
combination therapy for second-stage African Trypanosoma bru-
cei gambiense trypanosomiasis: a multicentre, randomised,
phase III, non-inferiority trial. Lancet 374, 56–64.
Rosenbaum, C., Rohrs, S., Muller, O., Waldmann, H., 2005.
Modulation of MRP-1-mediated multidrug resistance by indo-
methacin analogues. J. Med. Chem. 48, 1179–1187.
Sanderson, L., Khan, A., Thomas, S., 2007. Distribution of suramin,
an antitrypanosomal drug, across the blood–brain and
blood-cerebrospinal fluid interfaces in wild-type and
P-glycoprotein transporter-deficient mice. Antimicrob. Agents
Chemother. 51, 3136–3146.
Sanderson, L., Dogruel, M., Rodgers, J., Bradley, B., Thomas, S.A.,
2008. The blood–brain barrier significantly limits eflornithine
entry into Trypanosoma brucei brucei infected mouse brain. J.
Neurochem. 107, 1136–1146.
Sanderson, L., Dogruel,M., Rodgers, J., DeKoning, H.P., Thomas, S.A.,
2009. Pentamidine movement across the murine blood–brain
and blood-cerebrospinal fluid barriers: effect of trypanosome
infection, combination therapy, P-glycoprotein, and multidrug
resistance-associated protein. J. Pharmacol. Exp. Ther. 329,
967–977.
Sands, M., Kron, M.A., Brown, R.B., 1985. Pentamidine: a review.
Rev. Infect. Dis. 7, 625–634.
121B R A I N R E S E A R C H 1 4 3 6 ( 2 0 1 2 ) 1 1 1 – 1 2 1Sauer, S.W., Opp, S., Mahringer, A., Kaminski, M.M., Thiel, C.,
Okun, J.G., Fricker, G., Morath, M.A., Kolker, S., 2010. Glutaric
aciduria type I and methylmalonic aciduria: simulation of
cerebral import and export of accumulating neurotoxic
dicarboxylic acids in in vitro models of the blood–brain barrier
and the choroid plexus. Biochim. Biophys. Acta 1802, 552–560.
Schram, M.T., Chaturvedi, N., Schalkwijk, C., Giorgino, F., Ebeling,
P., Fuller, J.H., Stehouwer, C.D., 2003. Vascular risk factors and
markers of endothelial function as determinants of
inflammatory markers in type 1 diabetes: the EURODIAB
prospective complications study. Diabetes Care 26, 2165–2173.
Sugiyama, D., Kusuhara, H., Shitara, Y., Abe, T., Meier, P.J., Sekine, T.,
Endou, H., Suzuki, H., Sugiyama, Y., 2001. Characterization of the
efflux transport of 17beta-estradiol-D-17beta-glucuronide from
the brain across the blood–brain barrier. J. Pharmacol. Exp. Ther.
298, 316–322.
Suzuki, M., Suzuki, H., Sugimoto, Y., Sugiyama, Y., 2003. ABCG2
transports sulfated conjugates of steroids and xenobiotics. J.
Biol. Chem. 278, 22644–22649.
Tai, L.M., Loughlin, A.J., Male, D.K., Romero, I.A., 2009a.
P-glycoprotein and breast cancer resistance protein restrict
apical-to-basolateral permeability of human brain
endothelium to amyloid-beta. J. Cereb. Blood Flow Metab.
29, 1079–1083.
Tai, L.M., Reddy, P.S., Lopez-Ramirez, M.A., Davies, H.A., Male,
D.K., Loughlin, A.J., Romero, I.A., 2009b. Polarized P-
glycoprotein expression by the immortalised human brain
endothelial cell line, hCMEC/D3, restricts apical-to-basolateral
permeability to rhodamine 123. Brain Res. 1292, 14–24.
Ueda, K., Okamura, N., Hirai, M., Tanigawara, Y., Saeki, T., Kioka,
N., Komano, T., Hori, R., 1992. Human P-glycoprotein
transports cortisol, aldosterone, and dexamethasone, but not
progesterone. J. Biol. Chem. 267, 24248–24252.Van Nieuwenhove, S., 1992. Advances in sleeping sickness
therapy. Ann. Soc. Belg. Med. Trop. 72 (Suppl 1), 39–51.
Vander Borght, S., Van Pelt, J., Van Malenstein, H., Cassiman, D.,
Renard, M., Verslype, C., Libbrecht, L., Roskams, T.A., 2008.
Up-regulation of breast cancer resistance protein expression in
hepatoblastoma following chemotherapy: a study in patients
and in vitro. Hepatol. Res. 38, 1112–1121.
Wang, Q., Liang, B., Shirwany, N.A., Zou, M.H., 2011. 2-Deoxy-D-
glucose treatment of endothelial cells induces autophagy by
reactive oxygen species-mediated activation of the
AMP-activated protein kinase. PLoS One 6, e17234.
Weiss, J., Rose, J., Storch, C.H., Ketabi-Kiyanvash, N., Sauer, A.,
Haefeli, W.E., Efferth, T., 2007. Modulation of human BCRP
(ABCG2) activity by anti-HIV drugs. J. Antimicrob. Chemother.
59, 238–245.
Weksler, B.B., Subileau, E.A., Perriere, N., Charneau, P., Holloway,
K., Leveque, M., Tricoire-Leignel, H., Nicotra, A., Bourdoulous,
S., Turowski, P., Male, D.K., Roux, F., Greenwood, J., Romero,
I.A., Couraud, P.O., 2005. Blood–brain barrier-specific proper-
ties of a human adult brain endothelial cell line. FASEB J. 19,
1872–1874.
Whiteman, M., Hooper, D.C., Scott, G.S., Koprowski, H., Halliwell,
B., 2002. Inhibition of hypochlorous acid-induced cellular
toxicity by nitrite. Proc. Natl. Acad. Sci. U. S. A. 99, 12061–12066.
Wojtal, K.A., De Vries, E., Hoekstra, D., Van Ijzendoorn, S.C., 2006.
Efficient trafficking of MDR1/P-glycoprotein to apical
canalicular plasma membranes in HepG2 cells requires
PKA-RIIalpha anchoring and glucosylceramide. Mol. Biol. Cell
17, 3638–3650.
Yun, O., Priotto, G., Tong, J., Flevaud, L., Chappuis, F., 2010. NECT is
next: implementing the new drug combination therapy for
Trypanosoma brucei gambiense sleeping sickness. PLoS Negl.
Trop. Dis. 4, e720.
